Breakthrough with Animal Vaccine Development
Another breakthrough with Animal Vaccine Development was achieved by VEROVACCiNES GmbH, an accelerator participant and tenant of the Technologiepark Weinberg Campus.
As of the 4th of March 2021 VEROVACCiNES GmbH that participates in the Weinberg Campus Accelerator is able to protect target animals against viral challenges in its 4th Animal Vaccine Program.
Congratulations and keep up the good work.
Read the whole announcement here.
About VEROVACCiNES GmbH
VerovaccinesGmbH is a spin-off of Prof. Dr. Sven-Erik Behrens, Dr. Hanjo Hennemann and Dr. Martina Behrens from the Martin Luther University Halle-Wittenberg, Germany. In addition to the experienced founders, the company has a staff of scientists with expertise in the fields of virology, molecular biology, veterinary medicine and process engineering. Several of the company’s ownvaccine development programs are funded by the “Gründungsoffensive Biotechnologie”, or GO-Bio for short, of the German Federal Ministry of Education and Research (BMBF). (Source: www.verovaccines.org/)
Weinberg Campus Accelerator on Social Media